Experiments were designed to test the hypothesis that chronic exposure to tumor necrosis factor alpha (TNF) 
Introduction
The short-term effects of the cytokine tumor necrosis factor alpha (TNF)' have been studied extensively in vitro. A detailed 1 . Abbreviations used in this paper: IDA, index of disease activity; LT, lymphotoxin; PE, phycoerythrin; PPD, purified protein derivative; SkSd, Streptokinase/Streptodomase; Tac, Tac antigen (1L-2R alpha chain); TNF-R, tumor necrosis factor receptor.
analysis reveals a pattern of responses that are considered immunostimulatory or proinflammatory (reviewed in reference 1). For example, TNF is a growth factor for T and B cells (2, 3) , a potent activator of macrophages (4) , and induces the production of proinflammatory mediators such as prostaglandins and collagenase (5) and other cytokines such as interleukin-l (IL-1) (6, 7) , , and granulocyte-macrophage colony stimulating factor (GM-CSF) by both hemopoetic and nonhemopoeitic cells (9, 10) . During acute inflammatory responses these proinflammatory effects may be amplified further by TNF through upregulation of adhesion molecules intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1 on endothelium (1 1) , and by the induction of chemoattractants such as IL-8 (12) , thereby facilitating the trafficking of cells to sites of inflammation.
The long-term effects of TNF in disease, on the other hand, have been more difficult to define. Some clues have been provided by clinical studies of chronic inflammatory disease such as rheumatoid arthritis (RA), multiple sclerosis (13) , and Crohn's disease (14) , and chronic infections such as malaria (15) , tuberculosis, and leishmaniasis (16) , in which TNF expression is augmented. For example, one clinical manifestation thought to be related to chronic TNF exposure in vivo is the wasting syndrome known as cachexia, particularly characteristic of chronic parasitic infestation and malignancy (1, 17) , but also a recognized feature of many chronic inflammatory diseases (18) . There are other features of these conditions, such as immune dysfunction, which could also be due to sustained overproduction of cytokines, but which have not been investigated in any detail at the cellular level. Thus, detailed study of the long-term effects of TNF on cells present at sites of inflammation would be of interest, and might enhance our understanding of the cellular and molecular mechanisms that contribute to the pathogenesis of chronic inflammatory disease.
RA is a chronic inflammatory disease in which local, sustained overproduction of cytokines such as IL-1, IL-6, IL-8, GM-CSF, and TNF has been reported (19) . Synovial cells, chiefly comprising monocytes and activated T cells, with fewer fibroblasts, produce TNF spontaneously in culture (20, 21) . In addition, they express high levels of TNF receptors (TNF-R) which are sustained for many days in culture, in contrast to the transient expression of some cytokine receptors (e.g., IL-2R, as well as TNF-R) observed on PHA and IL-2 stimulated peripheral blood mononuclear cells (PBMC) (22) . These abnormal cytokine responses, and the notable reduction of inflammatory mediators by neutralizing TNF in RA synovial cultures (23, 24) , have implicated TNF in the pathogenesis of RA (19) (20) (21) (22) (23) (24) . The development of a spontaneous arthritis in mice expressing a human TNF transgene modified by exchanging the 3' untrans-and perpetuate arthritis (25) . This concept has also been supported by animal models of human RA such as collagen-induced arthritis in DBA/1 mice, in which anti-TNF antibody even when administered after the onset of arthritis ameliorates synovial hyperplasia and joint destruction (26) . More recently, in an open phase I/II study, significant clinical benefit has been observed in RA patients receiving treatment with a neutralizing chimeric monoclonal antibody to TNF, cA2 (27) . This important finding confirms that augmented expression of TNF persists in vivo for prolonged periods in rheumatoid patients and contributes to the processes that lead to active disease.
T lymphocytes are the predominant cell type in chronic rheumatoid synovial infiltrates (28) . They express activation antigens such as VLA-4, LFA-1, class II major histocompatibility (MHC) molecules, and to a lesser extent IL-2R (29, 30) . Since bioactive TNF is detectable in synovial joint cell cultures, as well as in synovial fluid (21) , it is likely that synovial joint T cells overexpressing TNF-R are persistently exposed to TNF in vivo. These characteristics are similar to T cell lines or clones, which, when cultured in vitro for prolonged periods, are chronically activated, secrete abundant TNF (31) , and express high levels of TNF-R (32, and A. Cope, unpublished data). Therefore, we decided to study cultures of antigen-specific T cell clones derived from normal individuals as a model system for investigating the long-term effects of TNF in vitro. Our data suggest that chronic exposure to bioactive TNF in vivo could account for some of the abnormal features of T cells derived from RA patients, such as impaired antigen and mitogen responses, and suppressed lymphokine production (33, 34, 35) . Furthermore, studies of cell-mediated immune responses in RA patients before and after treatment with anti-TNF have confirmed our in vitro observations, demonstrating that TNF exerts suppressive effects on cellular responses in vivo.
Methods
T cells and cell culture conditions. All T cells were cultured in RPMI 1640 (Gibco, Paisley, Scotland), supplemented with 10% heat inactivated AB normal human serum, 2 mM L-glutamine, 25 mM Hepes, antibiotics, and 20 ng/ml purified recombinant human IL-2 (HoffmannLa Roche, Nutley, NJ), (complete medium, endotoxin < 50 pg/ml by the limulus amebocyte assay). Four tetanus toxoid-specific T cell clones were generated from antigen-reactive T cell lines derived from the peripheral blood of two normal healthy individuals as previously described (36 The presence of bioactive IL-2 in these culture supernatants was determined using the IL-2 dependent murine CT6 T cell line as described (37) . Briefly, 48 h culture supernatants were harvested from T cells stimulated with immobilized OKT3 in the presence of saturating concentrations of anti-Tac antibody, and added in twofold serial dilutions in triplicate to round bottomed 96-well culture trays containing 5 x 104 CT6 cells/well. Proliferation of CT6 cells was determined by incorporation of [3H]thymidine for the last 4 h of 24 h assays. Cells were harvested as described above. The amount of IL-2 was determined from the cpm produced by a standard curve using recombinant human IL-2.
Proliferative responses ofPBMCfrom RA patients treated with cA2. Six RA patients with longstanding active disease, and who fulfilled the revised 1988 American Rheumatism Association diagnostic criteria for rheumatoid arthritis, were studied (38) . Details of these patients, all of whom had failed therapy with multiple disease modifying agents, are reported elsewhere (27) . Heparinized whole blood was obtained from patients on day 0, prior to commencing anti-TNF treatment (10 mg/kg cA2, i.v.), on day 1 (24 h later), and at days 7, or 28 as indicated. Patients received a second infusion of cA2 on day 14. Clinical scores for each patient were assessed during anti-TNF treatment using a composite index of disease activity (IDA, range 1-4) (39). All PBMC were obtained by density centrifugation as described above and cryopreserved prior to study. Serial unfractionated PBMC samples from each patient were then studied at the same time (to avoid interassay variability) for their proliferative responses to a panel of mitogens and soluble antigens. Thawed PBMC from each time point were washed, counted, and resuspended at 106 cells/ml. To 96-well round-bottomed trays containing 100 jul of this cell suspension was added 100 M1 of either medium alone, or medium containing optimal concentrations of IL-2 (20 ng/ml), OKT3
(50 ng/ml), PHA (4 jg/ml), concanavalin A (4 jig/ml) (Sigma Chemical Co.), tetanus toxoid (1/100 dilution), tuberculin purified protein derivative (PPD, 10 Fig. 3 shows the results of these proliferative responses expressed as stimulation indices, representative of three independent experiments. We observed significant reductions in tetanus-specific proliferative responses on rechallenge of T cells treated with 10 ng/ml TNF or more (P < 0.002; Fig. 3 In the second, both groups of cells underwent a stimulation cycle in the absence of exogenous TNF. Rechallenge after the first cycle showed significant reduction in tetanus specific responses. Following a full cycle of stimulation (-2 wk) in the absence of exogenous TNF, antigen specific responses of these cells in a second recall assay were comparable to control levels (reduction 1%).
Together these experiments-demonstrate that chronic exposure to TNF suppresses antigen-specific T cell responses irrespective of the type or presence of antigen-presenting cells, the initial stimulus, or the presence of prostaglandins. Furthermore, these effects are reversible in vitro, arguing against the likelihood of cytotoxic effects. Endogenous TNF production has suppressive effects. T cell clones cultured in vitro are chronically activated and secrete abundant TNF (31) . Since a reduction in antigen-specific responses occurred at TNF concentrations between 1 and 10 ng/ ml, we reasoned that endogenous TNF produced spontaneously by T cell clones in culture could exert similar effects. Furthermore, it was possible that membrane-associated TNF expressed on these cells (data not shown) would also contribute to the levels of endogenous TNF bioactivity. Therefore we stimulated clone 25 (which produces TNF; see Fig. 4 shows the results (representative of five experiments) of proliferative responses of cells pretreated with complete medium, TNF or anti-TNF to increasing concentrations of immobilized OKT3, harvested 3 (Fig. 4 A) or 7 d after stimulation (Fig. 4 B) . While TNF reduced these responses, cells pretreated with anti-TNF demonstrated significantly enhanced proliferation (P < 0.05). Although significant differences were observed between treatments for all concentrations of OKT3, they were most marked at suboptimal concentrations. The differences in proliferation between the three pretreatments observed after 7 d of stimulation with OKT3, however, indicated that the cells had begun to recover, since the suppression or enhancement induced by TNF or anti-TNF, respectively, was less marked. These data suggested that the levels of endogenous TNF expressed in soluble and membrane form following stimulation of T cells are sufficient to exert suppressive effects.
Effects of TNF on expression of cell surface antigens. Significant reductions in OKT3 induced proliferation of TNF pretreated cells suggested the possibility of a perturbation of the IL-2/IL-2R system by chronic exposure of T cells to TNF. To address this, we evaluated cell surface Tac expression (IL-2Ra chain) on cells pretreated with or without TNF, or with anti-TNF, and compared these findings with the expression of CD3, CD4, and HLA-DR (Fig. 5) . We observed several patterns of surface antigen expression with chronic TNF treatment. Thus, prior to OKT3 stimulation, the expression of Tac and HLA-DR were upregulated as reported previously (32, 40) , while levels of CD3 and CD4 antigens did not change with TNF treatment. However, upon stimulation with immobilized OKT3, levels of Tac on untreated cells were dramatically increased, while levels on TNF pretreated cells changed little from prestimulation levels; upregulation of IL-2R was thus impaired. By contrast, there were no changes noted in the expression of CD3, CD4, or HLA- Effects of TNF pretreatment on lymphokine production. The effects of TNF observed on subsequent stimulation of T cells through the TCR/CD3 complex described above (Fig. 1, 4 , and 5), raised the possibility that TNF might in someway modulate T cell function by modulating the production of T cell growth factors such as IL-2, or immunoregulatory cytokines such as IL-10. We therefore compared the production of six lymphokines in 48 h culture supernatants of T cells cultured under normal conditions with those produced by T cells pretreated with TNF or anti-TNF. (27) . The results from patient 17, expressed as cpm, are illustrated in Fig. 6 , and the data from all six patients are summarized in Table Im . For patient 17, proliferative responses were evaluated before treatment and on days 7 and 28 after anti-TNF therapy.
Responses to all mitogens and recall antigens except PHA, were markedly impaired before treatment. Within 7 d, increases in all mitogen responses were observed, including those to IL-2, while an increase in PPD response was also noted. By day 28, further significant increases were noted for all mitogens and antigens (P < 0.03), including tetanus toxoid, to which responses were lower than those to PPD and SkSd. Similar patterns were observed over this time period when responses to suboptimal concentrations of mitogen and antigen were tested (see Table Ill ). 21 . Nevertheless, both clinical and cellular responses at day 21 were still increased above those observed on day 0. Responses to tetanus toxoid precluded statistical analysis, while the remaining responses revealed significant differences between pretreatment and peak stimulation indices posttherapy for IL-2, OKT3, Con A, PPD, and SkSd (P < 0.04), but not PHA (P > 0.05).
Discussion
A detailed knowledge of the short-term effects of TNF on cells cultured in vitro has enhanced our understanding of the role of TNF in pathophysiology (1) . Much of the data reported to date have addressed the mechanisms by which TNF contributes to the inflammatory response through its effects on monocytes and macrophages. These cells constitutively express TNF-R (41) and stimulation with TNF induces cell activation, enhancement of phagocytic activity, and induction of the respiratory burst (4) investigation of TNF effects on T cells. Since the beneficial effects of neutralizing TNF in RA patients suggested that TNF expression persists in vivo for prolonged periods (27) , an evaluation of the chronic effects of TNF seemed clinically relevant. We chose to study antigen-specific T cell clones from healthy individuals, since the specificity of antigen responses in the joints of RA patients is not known. Using this in vitro model, our investigations revealed several interesting and unexpected findings. Firstly, chronic TNF exposure resulted in significant dose-and time-dependent reductions in responses of T cells when stimulated subsequently through the TCR/CD3 complex, but not through the IL-2R. Secondly, under these conditions TNF caused a significant reduction in lymphokine production. Thirdly, stimulation of TNF-treated T cells led to suboptimal expression of Tac following activation. Finally, although concentrations of exogenous TNF required to induce suppressive effects were high (> 10 ng/ml), levels of endogenous TNF expressed by chronically activated T cell clones either in soluble or membrane form were sufficient to exert similar suppressive effects in culture, since prolonged TNF blockade with mAb in vitro enhanced both proliferative responses and lymphokine production. These properties would appear not to be a characteristic exclusive to TNF. Thus, we have begun to screen the effects of other cytokines for their effects on antigenspecific responses and lymphokine production; preliminary data suggest that chronic exposure to IL-1, but not to IL-6, can impair TCR-specific responses (A. Cope, unpublished data). Direct comparisons of the relative potency of TNF and IL-I on a molar basis are in progress. On the other hand, equimolar concentrations of lymphotoxin (LT), which binds to the same receptors as TNF, induced less potent suppression of antigenspecific responses and lymphokine production compared with TNF-treated cultures. In this regard, LT has been shown to be less biologically active in several in vitro biological systems (42) , with distinct activities from those of TNF (43) . The reasons for these differences remain obscure.
There is an extensive literature documenting the potentiating effects of TNF in immune responses in vivo. This is particularly well illustrated in anti-tumor cell responses (44) , as well as in animal models of allograft rejection (45), graft-versus-host disease (46) , antilisterial immunity (47) and granuloma formation in BCG immunized mice (48) . More recently, studies have demonstrated that anti-TNF, when administered to mice at the time of priming with antigen, interferes with the generation of both CD4 class H1-restricted T cells mediating contact sensitivity, and CD8 class I-restricted anti-hapten cytotoxic T lymphocyte responses (49) . That there were no obvious changes in the lymphoid populations in anti-TNF-treated animals suggested a functional effect of blocking TNF on cell-mediated immunity, rather than a direct lytic effect of antibody. Until now, there have been no detailed studies investigating the suppressive effects of TNF on human cells, although there is a report that TNF can suppress immune functions in mice. Thus, repeatedly injecting C57BIJ6 mice with TNF over an 8-wk period induced lymphocytopenia, suppressed the proliferative responses of splenocytes to Con A, PHA, and LPS, inhibited cytotoxicity against allogeneic targets, and delayed type hypersensitivity reactivity, and completely abolished NK cell activity, while no effects on humoral immunity could be detected (50) . A defect in accessory cell function rather than a direct effect on T cells was considered the likely mechanism, possibly resulting from the enhanced production of PGE2 induced by TNF. In contrast to these studies, our data demonstrated a direct effect of TNF on T cells, since we observed suppressive effects in vitro in the absence of antigen presenting cells. Furthermore, the suppressive effects of TNF were not cytostatic, and were equally potent in the presence of cyclooxygenase inhibitors.
Although a direct comparison between animal studies and those of our own are difficult, kinetic analyses in vitro and in vivo revealed that optimal suppression by TNF takes several days to develop. This implies that TNF may exert its suppressive effects by modulating the production of secondary mediators were as follows: IL-2 (20 ng/ml:5 ng/ml), OKT3 (50 ng/ml:10 ng/ml), PHA (4 ,g/ml: 1jig/ml), Con A (4 jig/ml:0.5 ,g/ml), tetanus toxoid
(1/100:1/5000), PPD (10 jig/ml:2.5 jig/ml) and SkSd (5 jig/ml: 1 jig/ml); 1 1 statistically significant differences between day 0 and peak stimulation indices for mitogens and antigens are shown.
such as cytokines or cell surface receptors. Under these circumstances, changes in T cell function might take days to develop. Accordingly, our studies demonstrated that chronic TNF exposure impaired OKT3-induced lymphokine production. Levels of all lymphokines detectable were significantly reduced, suggesting a potent, but nevertheless nonselective effect. Of particular significance was the downregulation of OKT3-induced IL-2 production by TNF treatment, a feature which together with impaired IL-2R expression, could provide one important mechanism for the impaired growth responses of these cells. While TNF and LT production were reduced to below detectable limits in one experiment, levels of IL-10 were undetectable in both experiments. This raises the intriguing possibility that impairment of T cell function by TNF could arise from more subtle alterations in the profile of lymphokines they produce, rather than the more striking differences reported for lymphokines expressed by CD4 T cells of the THI or TH2 subsets in mice (51) . In our experiments, IL-2 and IFNy levels were reduced following TNF pretreatment, even though significant levels of these lymphokines were still detectable, whereas levels of IL-10, a cytokine with inhibitory properties (52), were undetectable. By contrast, IL-10 production was increased more than six-to sevenfold by neutralizing endogenous TNF production with anti-TNF mAb, while IL-2, and IFNy levels increased only twofold. In this way, chronic TNF expression could disturb a delicate balance between levels of immunoregulatory and stimulatory lymphokines. An alternative possibility is that other cytokines that have not been investigated in this study are preferentially induced. At present we have not excluded the possibility that TNF in long-term culture selectively upregulates the production of TGF/3 by T cells, although there is no precedent for this on the basis of studies in short-term cell cultures (53) . In this regard, experiments have been performed on IL-4 producing clones to examine the effects of chronic TNF on the production of this growth factor, a lymphokine with potent antiinflammatory properties on some cell types (54, 55 (56, 57) , it is conceivable that this form of the molecule contributes to the suppressive effects induced by endogenously expressed 758 TNF. If so, this provides a novel mechanism by which cA2 can regulate immune function in the absence of detectable levels of soluble TNF. Partly because it is difficult to quantitate, the contribution of membrane TNF to normal and inflammatory responses is very likely to be underestimated; a comparison of the capacity for different TNF inhibitors to neutralize the activity of surface ligand will help to define the relative contribution of membrane and soluble TNF in this and other biological systems.
Although there is abundant evidence that the immune function of patients with severe RA is not normal (33, 58, 59) , there is little consensus as to the mechanisms of this immune suppression. Thus, the proliferative responses of both PBMC and synovial mononuclear cells to mitogens, recall antigens, the mixed lymphocyte reaction and, in cases of severe RA, IL-2 are markedly impaired. Furthermore, treatment of immunosuppressed patients with anti-TNF antibody, which has potent immunosuppressive properties in vitro, presents the potential risk of further suppressing immune function. On the other hand, the in vitro data reported here suggested to us that blocking endogenous TNF might have the effect of restoring cellular immune functions, by releasing T cells of the suppressive effects of chronic TNF exposure in vivo. In order to address which of these effects predominate in vivo, we studied T cell receptor and mitogen-specific responses of unfractionated mononuclear cell populations from patients with longstanding active RA before and immediately after treatment with anti-TNF. Consistent with our in vitro data, anti-TNF treatment in patients enhanced the proliferative responses of PBMC to a panel of T cell mitogens and recall antigens ( Fig. 6 and Table III) . Furthermore, these changes, which were observed within days of commencing anti-TNF treatment, appeared to parallel the rapid improvements observed in disease activity, irrespective of whether changes in clinical indices were sustained or transient. At this time, we have no evidence that the clinical benefit seen is related to improvements in T cell immunity. One possibility is that TNF exerts its effects in vivo by impairing accessory cell function, although the finding that populations of synovial or peripheral blood accessory cells from RA patients are potent stimulators of autologous mixed lymphocyte reactions would argue against this (60) . Another possibility relates to TNF and its role in cell trafficking (11), a process whose modulation could alter significantly the populations of cells within the peripheral blood compartment. For example, no changes in the proportion of CD4+ T cells in PBMC have been noted following cA2 treatment, while small increases in the proportion of CD45RO+ "memory" T cells were observed in three patients evaluated (unpublished data). Clearly, studies are required to establish whether these increased responses reflect qualitative and/or quantitative effects of TNF on memory T cells in vivo. Further investigations of patients and animals will allow us to define precisely how the beneficial effects of anti-TNF on disease activity and immune function are interlinked. Nevertheless, our data support the hypothesis that chronic TNF exposure in vivo dampens cellular immune responses. More importantly from the clinical point of view, treatment of immunosuppressed patients with anti-TNF does not further suppress cellular immunity, but rather enhances these responses, restoring them towards normal. This finding may be of considerable practical importance in the treatment of diseases in which TNF blockade is beneficial to patients.
